STOK Nasdaq Pharmaceutical Preparations Financials FY2018βFY2025
Stoke Therapeutics, Inc. had $184M of revenue in fiscal 2025, up 404.5% on the year before.
Last close Β· Oct 23, 2026
$25.04
2.6%Hi! I read Stoke Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+404.5%
Yes. Sales grew 404.5% last year.
Does it make a profit?
β3.7%
No. It lost money last year.
Does profit turn into cash?
24.4%
Yes. 24.4% of sales ends up as free cash.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Stoke Therapeutics, Inc. had $184M of revenue in fiscal 2025, up 404.5% on the year before. Its operating margin was β11.2%, up 266.1Β pts: of every 100 in sales, about β11 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Stoke Therapeutics, Inc. lost $6.9M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $44.9M in fiscal 2025, 24.4% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $8.9M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$8.9M
8 insiders
Of sales under plans
83%
$7.4M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | Jonathan AllanGeneral Counsel & Corp Sec | Sold plan | 627 | $26.33 | $0.0M | Form 4 |
| Oct 1, 2026 | Barry TichoChief Medical Officer | Sold plan | 1,051 | $26.16 | $0.0M | Form 4 |
| Sep 1, 2026 | Barry TichoChief Medical Officer | Sold plan | 5,545 | $30.67 | $0.2M | Form 4 |
| Aug 18, 2026 | Edward M. Kaye MDDirector | Sold | 12,567 | $32.03 | $0.4M | Form 4 |
| Aug 18, 2026 | Jonathan AllanGeneral Counsel & Corp Sec | Sold | 2,861 | $32.03 | $0.1M | Form 4 |
| Aug 18, 2026 | Barry TichoChief Medical Officer | Sold | 4,767 | $32.03 | $0.2M | Form 4 |
| Aug 3, 2026 | Barry TichoChief Medical Officer | Sold plan | 7,176 | $29.04 | $0.2M | Form 4 |
| Jul 1, 2026 | Barry TichoChief Medical Officer | Sold plan | 7,228 | $32.67 | $0.2M | Form 4 |
| Jun 16, 2026 | Jonathan AllanGeneral Counsel & Corp Sec | Sold plan | 1,457 | $29.95 | $0.0M | Form 4 |
| Jun 1, 2026 | Barry TichoChief Medical Officer | Sold plan | 1,795 | $30.58 | $0.1M | Form 4 |
| May 1, 2026 | Barry TichoChief Medical Officer | Sold plan | 2,243 | $32.79 | $0.1M | Form 4 |
| Apr 1, 2026 | Barry TichoChief Medical Officer | Sold plan | 1,838 | $32.66 | $0.1M | Form 4 |
| Mar 20, 2026 | Jonathan AllanGeneral Counsel & Corp Sec | Sold plan | 9,293 | $33.69 | $0.3M | Form 4 |
| Mar 19, 2026 | Barry TichoChief Medical Officer | Sold plan | 1,461 | $29.99 | $0.0M | Form 4 |
| Mar 18, 2026 | Jonathan AllanGeneral Counsel & Corp Sec | Sold | 4,628 | $31.34 | $0.1M | Form 4 |
| Mar 18, 2026 | Jason HoittChief Patient Officer | Sold | 1,931 | $31.34 | $0.1M | Form 4 |
| Mar 18, 2026 | Thomas LeggettChief Financial Officer | Sold | 2,382 | $31.34 | $0.1M | Form 4 |
| Mar 18, 2026 | Barry TichoChief Medical Officer | Sold plan | 6,686 | $31.34 | $0.2M | Form 4 |
| Mar 17, 2026 | Barry TichoChief Medical Officer | Sold plan | 6,164 | $33.01 | $0.2M | Form 4 |
| Mar 17, 2026 | Jonathan AllanGeneral Counsel & Corp Sec | Sold | 4,267 | $33.01 | $0.1M | Form 4 |
| Mar 17, 2026 | Thomas LeggettChief Financial Officer | Sold | 2,196 | $33.01 | $0.1M | Form 4 |
| Mar 17, 2026 | Jason HoittChief Patient Officer | Sold | 1,781 | $33.01 | $0.1M | Form 4 |
| Mar 13, 2026 | Arthur A LevinDirector | Sold plan | 605 | $36.80 | $0.0M | Form 4 |
| Mar 10, 2026 | Arthur TzianabosInterim Executive Chair, Director | Sold plan | 4,355 | $40.00 | $0.2M | Form 4 |
| Mar 10, 2026 | Adrian R. KrainerDirector | Sold plan | 33,243 | $39.74 | $1.3M | Form 4 |
| Mar 2, 2026 | Adrian R. KrainerDirector | Sold plan | 7,229 | $39.66 | $0.3M | Form 4 |
| Dec 8, 2025 | Jonathan AllanGeneral Counsel & Corp Sec | Sold plan | 3,978 | $32.28 | $0.1M | Form 4 |
| Dec 8, 2025 | Edward M. Kaye MDDirector | Sold plan | 13,430 | $32.27 | $0.4M | Form 4 |
| Dec 5, 2025 | Edward M. Kaye MDDirector | Sold plan | 8,548 | $31.33 | $0.3M | Form 4 |
| Dec 5, 2025 | Jonathan AllanGeneral Counsel & Corp Sec | Sold plan | 8,785 | $31.29 | $0.3M | Form 4 |
| Dec 5, 2025 | Barry TichoChief Medical Officer | Sold plan | 3,662 | $31.34 | $0.1M | Form 4 |
| Dec 4, 2025 | Edward M. Kaye MDDirector | Sold plan | 6,453 | $30.87 | $0.2M | Form 4 |
| Dec 4, 2025 | Jonathan AllanGeneral Counsel & Corp Sec | Sold plan | 1,018 | $30.87 | $0.0M | Form 4 |
| Dec 4, 2025 | Barry TichoChief Medical Officer | Sold plan | 1,696 | $30.87 | $0.1M | Form 4 |
| Dec 3, 2025 | Edward M. Kaye MDDirector | Sold | 1,070 | $30.65 | $0.0M | Form 4 |
| Dec 3, 2025 | Jonathan AllanGeneral Counsel & Corp Sec | Sold | 2,292 | $30.65 | $0.1M | Form 4 |
| Dec 3, 2025 | Barry TichoChief Medical Officer | Sold | 2,014 | $30.65 | $0.1M | Form 4 |
| Dec 2, 2025 | Edward M. Kaye MDDirector | Sold | 1,066 | $29.78 | $0.0M | Form 4 |
| Dec 2, 2025 | Barry TichoChief Medical Officer | Sold | 2,006 | $29.78 | $0.1M | Form 4 |
| Dec 2, 2025 | Jonathan AllanGeneral Counsel & Corp Sec | Sold | 2,284 | $29.78 | $0.1M | Form 4 |
| Nov 24, 2025 | Adrian R. KrainerDirector | Sold plan | 40,472 | $29.72 | $1.2M | Form 4 |
| Nov 14, 2025 | Adrian R. KrainerDirector | Sold plan | 40,472 | $26.98 | $1.1M | Form 4 |
| Nov 3, 2025 | Barry TichoChief Medical Officer | Sold plan | 5,931 | $25.72 | $0.2M | Form 4 |
| Oct 8, 2025 | Edward M. Kaye MDDirector | Sold plan | 25,000 | $30.00 | $0.8M | Form 4 |
| Oct 3, 2025 | Jonathan AllanGeneral Counsel & Corp Sec | Sold plan | 10,000 | $25.07 | $0.3M | Form 4 |
| Oct 3, 2025 | Edward M. Kaye MDDirector | Sold plan | 42,461 | $25.09 | $1.1M | Form 4 |
| Oct 1, 2025 | Barry TichoChief Medical Officer | Sold plan | 5,343 | $23.64 | $0.1M | Form 4 |
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Stoke Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $220M | $230M | $201M | $217M | $285M |
| Interest coverage | β | β | β2,342.3x | β3,898.9x | β2,287.8x |
| Current ratio | 13.4x | 7.8x | 7.0x | 5.8x | 5.3x |
| Quick ratio | 13.4x | 7.8x | 7.0x | 5.8x | 5.3x |
| Total assets | $239M | $256M | $228M | $272M | $418M |
| Total liabilities | $21.1M | $71.2M | $68.8M | $42.5M | $66.0M |
| Shareholders' equity | $218M | $185M | $160M | $229M | $352M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Stoke Therapeutics, Inc. passes 4 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | β / 6 | β / 6 | 1 / 7 | 3 / 7 | 4 / 7 |
| Accruals ratio | β1.4% | β0.8% | β3.8% | β7.0% | β28.0% | β9.8% | β0.9% | β15.2% |
| Altman Z'' | 49.39 | 59.01 | 29.17 | 11.57 | 1.65 | β1.38 | 1.91 | 5.29 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | β | β | β | β | $12.4M | $8.8M | $36.6M | $184M |
| Research and development | $8.4M | $23.8M | $32.2M | $54.2M | $77.8M | $82.2M | $89.1M | $138M |
| Operating income | β$12.8M | β$35.7M | β$53.0M | β$86.1M | β$104M | β$115M | β$101M | β$20.6M |
| Interest expense | β | β | β | β | β | $0.0M | $0.0M | $0.0M |
| Income tax | β | β | β | β | β | β | β | $0.0M |
| Net income | β$12.5M | β$32.3M | β$52.2M | β$85.8M | β$101M | β$105M | β$89.0M | β$6.9M |
| Diluted EPS | β$17.65 | β$1.80 | β$1.56 | β$2.34 | β$2.60 | β$2.38 | β$1.65 | β$0.12 |
| Diluted shares | 0.00B | 0.02B | 0.03B | 0.04B | 0.04B | 0.04B | 0.05B | 0.06B |
| Cash flow | ||||||||
| Cash from operations | β$11.0M | β$31.1M | β$42.2M | β$66.9M | β$31.9M | β$81.1M | β$86.9M | $45.6M |
| Capital expenditure | $0.9M | $1.6M | $1.1M | $1.2M | $4.0M | $1.6M | $0.2M | $0.7M |
| Free cash flow | β$11.9M | β$32.7M | β$43.3M | β$68.1M | β$35.8M | β$82.7M | β$87.1M | $44.9M |
| Depreciation and amortization | $0.2M | $0.5M | $0.9M | $1.0M | $1.5M | $2.5M | $2.2M | $1.8M |
| Stock-based compensation | $0.2M | $1.9M | $5.8M | $16.5M | $22.9M | $25.3M | $27.5M | $32.2M |
| Balance sheet | ||||||||
| Cash and short-term investments | $105M | $222M | $287M | $220M | $230M | $201M | $217M | $285M |
| Current assets | $106M | $226M | $294M | $229M | $244M | $215M | $233M | $306M |
| Current liabilities | $2.5M | $4.1M | $11.4M | $17.1M | $31.4M | $30.8M | $40.1M | $57.9M |
| Property and equipment, net | $1.2M | $2.5M | $2.7M | $4.1M | $6.7M | $5.8M | $3.9M | $3.1M |
| Total assets | $108M | $229M | $298M | $239M | $256M | $228M | $272M | $418M |
| Total liabilities | $2.5M | $4.3M | $11.8M | $21.1M | $71.2M | $68.8M | $42.5M | $66.0M |
| Shareholders' equity | $105M | $224M | $286M | $218M | $185M | $160M | $229M | $352M |
| Margins | ||||||||
| Operating margin | β | β | β | β | β841.2% | β1,307.2% | β277.3% | β11.2% |
| EBITDA margin | β | β | β | β | β828.8% | β1,279.1% | β271.4% | β10.2% |
| Net margin | β | β | β | β | β814.7% | β1,192.5% | β243.4% | β3.7% |
| FCF margin | β | β | β | β | β288.8% | β941.7% | β238.1% | 24.4% |
| Returns | ||||||||
| Return on capital employed | β12.2% | β15.9% | β18.5% | β38.8% | β46.4% | β58.1% | β43.8% | β5.7% |
| Return on equity | β11.9% | β19.6% | β20.5% | β34.1% | β50.2% | β60.8% | β45.8% | β2.4% |
| Return on assets | β11.6% | β19.2% | β19.8% | β32.0% | β40.8% | β43.2% | β35.6% | β2.0% |
| Return on tangible equity | β11.9% | β14.4% | β18.3% | β39.4% | β54.7% | β65.6% | β38.9% | β2.0% |
| Growth | ||||||||
| Revenue growth | β | β | β | β | β | β29.2% | 316.3% | 404.5% |
| Share count change | β | 2,433.7% | 86.3% | 9.7% | 5.9% | 13.1% | 22.8% | 9.6% |
| Financial health | ||||||||
| Interest coverage | β | β | β | β | β | β2,342.3x | β3,898.9x | β2,287.8x |
| Current ratio | 43.0x | 55.1x | 25.7x | 13.4x | 7.8x | 7.0x | 5.8x | 5.3x |
| Quick ratio | 43.0x | 55.1x | 25.7x | 13.4x | 7.8x | 7.0x | 5.8x | 5.3x |
| Capital allocation | ||||||||
| Capex / revenue | β | β | β | β | 31.9% | 18.4% | 0.6% | 0.4% |
| Stock comp / revenue | β | β | β | β | 184.2% | 287.7% | 75.1% | 17.5% |
| Quality scores | ||||||||
| Piotroski F-score | β | β | β | β | β | 1.0 | 3.0 | 4.0 |
| Altman Z'' | 49.4 | 59.0 | 29.2 | 11.6 | 1.7 | β1.4 | 1.9 | 5.3 |
| Accruals ratio | β1.4% | β0.8% | β3.8% | β7.0% | β28.0% | β9.8% | β0.9% | β15.2% |
Source: SEC EDGAR XBRL filings (CIK 0001623526). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
